WALTHAM, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of three new clinical studies on DPNCheck ® , a point-of-care device that provides accurate and cost-effective screening, diagnosis, and monitoring of diabetic peripheral neuropathy (DPN).
84 percent of Americans living with chronic pain believe there is a stigma around opioid use; 90 percent are actively seeking alternative treatments WALTHAM, Mass. , June 21, 2018 (GLOBE NEWSWIRE) -- The opioid crisis continues to make headlines, but in the midst of this chaos, members of the
WALTHAM, Mass. , June 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it had achieved the first development milestone under its strategic collaboration with GSK Consumer Healthcare . A milestone payment of $3.8 Million was made by GSK.
WALTHAM, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that preliminary results from a study of Quell ® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12,
WALTHAM, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it will be participating in the 3rd annual Disruptive Growth & Healthcare Conference in New York City on May 8-9, 2018 sponsored by RHK Capital and ReedSmith.
WALTHAM, Mass. , April 24, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present two scientific posters at the upcoming 2018 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Vancouver, Canada , April 26-28 .
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended March 31, 2018 . The Company develops and markets novel therapies, based on neurostimulation
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended March 31, 2018 . The Company develops and markets novel therapies, based on neurostimulation
WALTHAM, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA , April 21-27 .
WALTHAM, Mass. , April 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that it plans to issue its 2018 first quarter financial results before the opening of the market on Thursday, April 19, 2018. The Company will host a conference call at 8:00 a.m., Eastern
